A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > BUSINESS
BUSINESS
- Stephen Hitchcock Tapped as Head of Pharma Research at Takeda
December 9, 2015
- Takeda Ties Up with US Biotech Cour on Immune Modulating Therapies
December 9, 2015
- Ethical Drug Sales Zoom 10.7% in October: Crecon Report
December 9, 2015
- Mega Mergers Not the Best Way to Get Drug Discovery Prowess: Astellas President
December 9, 2015
- Sovaldi Top-Prescribed Drug at Japanese Acute Hospitals in July-Sept.
December 8, 2015
- Belsomra Most Promoted Drug for GPs for 4 Months Running: Anterio
December 8, 2015
- Otsuka Seeks Japan Approval of Abilify for Juvenile Autism-Linked Excitability
December 8, 2015
- MM Treatment Ixazomib Extends PFS in PIII: Takeda
December 8, 2015
- Nothing Decided for Japan Market over Pfizer’s Allergan Acquisition: Umeda
December 7, 2015
- Global PII for Pediatric X-Linked Hypophosphatemia Yields Positive Data: Kyowa Kirin
December 7, 2015
- Kyowa Kirin Kicks Off Global PIII for Adult X-Linked Hypophosphatemia
December 7, 2015
- Unusualness of Hep C Market Not Being Understood, Gilead COO Says on Possible Sovaldi Re-Pricing
December 4, 2015
- Nichi-Iko Sells Off Shares Held in South Korean Firm
December 3, 2015
- GSK’s Drug Supplies Disrupted by Manufacturing Woes Overseas
December 2, 2015
- Japan NDA for IBS-C Drug Linaclotide Planned in 2016: Astellas
December 2, 2015
- Sumitomo Dainippon to Reinstate Hara as Drug Development Head
December 2, 2015
- Daiichi Sankyo to Shutter German Biotech Unit amid R&D Cost-Cut Drive
December 2, 2015
- Kyowa Kirin Launches Japan PIII Study for Regpara Successor
December 2, 2015
- Ole Moelskov Bech to Lead Novo Nordisk Japan from January
December 2, 2015
- Heptares Inks R&D Deal with Pfizer; Pfizer to Buy 3% Stake in Sosei for US$33 Million
December 2, 2015
ページ
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…